Goldman Sachs’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.08M | Buy |
|
|||||
|
2025
Q1 | $773K | Sell |
|
|||||
|
2024
Q4 | $1.05M | Buy |
|
|||||
|
2024
Q3 | $1.01M | Buy |
|
|||||
|
2024
Q2 | $733K | Buy |
|
|||||
|
2024
Q1 | $837K | Sell |
|
|||||
|
2023
Q4 | $698K | Sell |
|
|||||
|
2023
Q3 | $783K | Sell |
|
|||||
|
2023
Q2 | $1.14M | Buy |
|
|||||
|
2023
Q1 | $938K | Buy |
|
|||||
|
2022
Q4 | $1.17M | Buy |
|
|||||
|
2022
Q3 | $1.37M | Buy |
|
|||||
|
2022
Q2 | $1.61M | Buy |
|
|||||
|
2022
Q1 | $1.46M | Sell |
|
|||||
|
2021
Q4 | $2.5M | Sell |
|
|||||
|
2021
Q3 | $25M | Buy |
|
|||||
|
2021
Q2 | $8.17M | Buy |
|
|||||
|
2021
Q1 | $15.7M | Buy |
|
|||||
|
2020
Q4 | $10.2M | Buy |
|